RM Primary Logo - Humble.png
Revolution Medicines to Participate in Upcoming Investor Conferences
01 févr. 2024 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RM Primary Logo - Humble.png
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
04 janv. 2024 07h00 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RM Primary Logo - Humble.png
Revolution Medicines Completes Acquisition of EQRx
09 nov. 2023 09h10 HE | Revolution Medicines, Inc.
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning,...
RM Primary Logo - Humble.png
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
08 nov. 2023 11h30 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for...
RM Primary Logo - Humble.png
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
06 nov. 2023 16h05 HE | Revolution Medicines, Inc.
Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to...
RM Primary Logo - Humble.png
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.
01 nov. 2023 07h00 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RM Primary Logo - Humble.png
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
31 oct. 2023 16h15 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
RevolutionLogo.png
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
22 oct. 2023 02h30 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
13 oct. 2023 11h50 HE | Revolution Medicines, Inc.
Revolution Medicines reports encouraging clinical data for both RMC-6236 and RMC-6291, two pioneering RAS(ON) Inhibitors, at 2023 Triple Meeting
RevolutionLogo.png
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
04 oct. 2023 16h05 HE | Revolution Medicines, Inc.
Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m....